WallStreetZenWallStreetZen

NASDAQ: BEAM
Beam Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BEAM

Based on 6 analysts offering 12 month price targets for Beam Therapeutics Inc

Min Forecast
$26.00-23.84%
Avg Forecast
$50.00+46.46%
Max Forecast
$74.00+116.75%

Should I buy or sell BEAM stock?

Based on 6 analysts offering ratings for Beam Therapeutics Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
2 analysts 33.33%
Hold
2 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BEAM's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BEAM as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BEAM stock forecasts and price targets.

BEAM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-13
lockedlocked$00.00+00.00%2026-03-26
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-20
UBS
Top 18%
83
HoldInitiates Coverage On$28.00-17.98%2026-01-07

1 of 1

Forecast return on equity

Is BEAM forecast to generate an efficient return?

Company
-31.53%
Industry
94.37%
Market
175.99%
BEAM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BEAM forecast to generate an efficient return on assets?

Company
-24.79%
Industry
27.62%
BEAM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BEAM earnings per share forecast

What is BEAM's earnings per share in the next 3 years based on estimates from 21 analysts?

Avg 1 year Forecast
-$4.50
Avg 2 year Forecast
-$4.62
Avg 3 year Forecast
-$4.54

BEAM revenue forecast

What is BEAM's revenue in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
$80.2M-51.08%
Avg 2 year Forecast
$96.9M-40.95%
Avg 3 year Forecast
$162.9M-0.66%
BEAM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BEAM revenue growth forecast

How is BEAM forecast to perform vs Biotechnology companies and vs the US market?

Company
-2.28%
Industry
34.07%
Market
14.06%
BEAM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BEAM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BEAM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BEAM$34.14$50.00+46.46%Buy
VKTX$30.38$104.00+242.33%Strong Buy
NAMS$29.83$46.67+56.44%Strong Buy
TLX$10.09$21.50+113.08%Strong Buy
DNLI$23.31$34.89+49.67%Strong Buy
View Top Biotech Stocks

Beam Therapeutics Stock Forecast FAQ

Is Beam Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: BEAM) stock is to Buy BEAM stock.

Out of 6 analysts, 2 (33.33%) are recommending BEAM as a Strong Buy, 2 (33.33%) are recommending BEAM as a Buy, 2 (33.33%) are recommending BEAM as a Hold, 0 (0%) are recommending BEAM as a Sell, and 0 (0%) are recommending BEAM as a Strong Sell.

If you're new to stock investing, here's how to buy Beam Therapeutics stock.

What is BEAM's earnings growth forecast for 2026-2028?

(NASDAQ: BEAM) Beam Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.

Beam Therapeutics's earnings in 2026 is -$65,040,000.On average, 21 Wall Street analysts forecast BEAM's earnings for 2026 to be -$463,131,358, with the lowest BEAM earnings forecast at -$479,910,957, and the highest BEAM earnings forecast at -$410,488,064. On average, 21 Wall Street analysts forecast BEAM's earnings for 2027 to be -$475,538,591, with the lowest BEAM earnings forecast at -$594,847,615, and the highest BEAM earnings forecast at -$330,550,915.

In 2028, BEAM is forecast to generate -$467,215,662 in earnings, with the lowest earnings forecast at -$713,817,138 and the highest earnings forecast at -$300,304,426.

What is BEAM's revenue growth forecast for 2026-2028?

(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -2.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Beam Therapeutics's revenue in 2026 is $164,011,000.On average, 20 Wall Street analysts forecast BEAM's revenue for 2026 to be $8,254,513,735, with the lowest BEAM revenue forecast at $3,528,757,040, and the highest BEAM revenue forecast at $14,777,570,299. On average, 20 Wall Street analysts forecast BEAM's revenue for 2027 to be $9,963,954,755, with the lowest BEAM revenue forecast at $3,427,935,410, and the highest BEAM revenue forecast at $24,452,331,584.

In 2028, BEAM is forecast to generate $16,762,110,337 in revenue, with the lowest revenue forecast at $2,974,238,077 and the highest revenue forecast at $37,264,908,895.

What is BEAM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BEAM) forecast ROA is -24.79%, which is lower than the forecast US Biotechnology industry average of 27.62%.

What is BEAM's Price Target?

According to 6 Wall Street analysts that have issued a 1 year BEAM price target, the average BEAM price target is $50.00, with the highest BEAM stock price forecast at $74.00 and the lowest BEAM stock price forecast at $26.00.

On average, Wall Street analysts predict that Beam Therapeutics's share price could reach $50.00 by May 13, 2027. The average Beam Therapeutics stock price prediction forecasts a potential upside of 46.46% from the current BEAM share price of $34.14.

What is BEAM's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BEAM) Beam Therapeutics's current Earnings Per Share (EPS) is -$0.50. On average, analysts forecast that BEAM's EPS will be -$4.50 for 2026, with the lowest EPS forecast at -$4.66, and the highest EPS forecast at -$3.99. On average, analysts forecast that BEAM's EPS will be -$4.62 for 2027, with the lowest EPS forecast at -$5.78, and the highest EPS forecast at -$3.21. In 2028, BEAM's EPS is forecast to hit -$4.54 (min: -$6.94, max: -$2.92).

What is BEAM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BEAM) forecast ROE is -31.53%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.